Rinsho Shinkeigaku (Clinical Neurology)

Case Report

A case of neurofascin-155 antibody-positive chronic inflammatory demyelinating polyradiculoneuropathy successfully treated with Cyclosporine A

Daisuke Sato, M.D.1), Hidenori Ogata, M.D., Ph.D.2), Motoi Kuwahara, M.D., Ph.D.3), Junichi Kira, M.D., Ph.D.2), Susumu Kusunoki, M.D., Ph.D.3) and Yoshihiro Suzuki, M.D., Ph.D.1)

1) Department of Neurology, Nihonkai General Hospital
2) Department of Neurology, Kyushu University Graduate School of Medicine
3) Department of Neurology, Kindai University Faculty of Medicine

A 41-year-old man noticed numbness of the fingers and toes, and gradually developed limb weakness and sensory impairment. The patient was diagnosed with typical chronic inflammatory demyelinating polyradiculoneuropathy. Over the course of clinical diagnosis, the limb and trunk ataxia, and finger tremor became prominent, and the presence antineurofascin-155 antibody was examined and confirmed positive. The effects of corticosteroids, intravenous immunoglobulin, and plasma apheresis were limited, and the disease progressed slowly and noticeably. Therefore, cyclosporine was introduced as treatment, and the patient's weakness and ataxia significantly improved. Rituximab treatment is expected to be effective in patients with the same antibody and immunosuppressant treatment may be useful in intractable cases.
Full Text of this Article in Japanese PDF (838K)

(CLINICA NEUROL, 60: 533|537, 2020)
key words: chronic inflammatory demyelinating polyradiculoneuropathy, neurofascin-155, first line therapy, intravenous immunoglobulin, Cyclosporine A

(Received: 17-Dec-19)